These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10558537)

  • 21. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Import and production quotas for certain List I chemicals. Interim final rule with request for comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Jul; 72(131):37439-53. PubMed ID: 17674492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prescriptions; dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration, Justice. Withdrawal of proposed rule.
    Fed Regist; 1983 Jun; 48(125):29713-4. PubMed ID: 10261481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Registration requirements for importers and manufacturers of prescription drug products containing ephedrine, pseudoephedrine, or phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Feb; 75(20):4973-82. PubMed ID: 20352663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2008 May; 73(100):29685-8. PubMed ID: 18605404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designation of oripavine as a basic class of controlled substance. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2007 Sep; 72(184):54208-10. PubMed ID: 17912784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Authorized sources of narcotic raw materials. Final rule.
    Fed Regist; 2008 Feb; 73(25):6843-51. PubMed ID: 18389916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of US and Canadian precursor regulation on methamphetamine purity in the United States.
    Cunningham JK; Liu LM; Callaghan R
    Addiction; 2009 Mar; 104(3):441-53. PubMed ID: 19207353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled substances and List I chemical registration and reregistration fees. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2012 Mar; 77(51):15234-50. PubMed ID: 22420065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exempt chemical mixtures containing gamma-butyrolactone. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Jun; 75(124):37301-7. PubMed ID: 20608286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2005 Jul; 70(144):43633-5. PubMed ID: 16050051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-certification and employee training of mail-order distributors of scheduled listed chemical products. Interim final rule with request for comment.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2011 Apr; 76(71):20518-24. PubMed ID: 21491808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are methamphetamine precursor control laws effective tools to fight the methamphetamine epidemic?
    Nonnemaker J; Engelen M; Shive D
    Health Econ; 2011 May; 20(5):519-31. PubMed ID: 21433216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schedules of controlled substances; table of excluded nonnarcotic products: nasal decongestant inhalers manufactured by Classic Pharmaceuticals, LLC. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2010 Mar; 75(55):13678-9. PubMed ID: 20383920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Mar; 69(53):12794-7. PubMed ID: 15029891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescriptions for Schedule II controlled substances: Drug Enforcement Administration, Justice. Notice of proposed rulemaking.
    Fed Regist; 1980 Apr; 45(70):24199-200. PubMed ID: 10246081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation of the Methamphetamine Anti-Proliferation Act; thresholds for retailers and for distributors required to submit mail order reports; changes to mail order reporting requirements. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Oct; 68(194):57799-804. PubMed ID: 14535265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration. Notice of proposed rulemaking.
    Fed Regist; 1982 Sep; 47(181):41140. PubMed ID: 10262071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dispensing of controlled substances to assist suicide. Interpretive rule.
    Department of Justice
    Fed Regist; 2001 Nov; 66(218):56607-8. PubMed ID: 11760766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.